TechTaffy

tech:

taffy

Exscientia, GlaxoSmithKline ink £33 million AI-driven drug discovery partnership

By TechTaffy Desk

Exscientia, a company that uses artificial intelligence and machine learning for drug discovery,  has entered into a collaboration with GlaxoSmithKline (GSK).

The company will receive research payments from GSK to undertake new discovery programs with nominated targets with the goal of delivering pre-clinical candidates. In addition to research funding, Exscientia is also eligible to receive near-term lead and pre-clinical candidate milestones. The total amount payable by GSK to Exscientia on achieving these milestones is £33 million.

During this collaboration, Exscientia will work with GSK to discover molecules for disease-related targets.

[Image courtesy: GSK]

Just in

Seed

Oso Semiconductor raises $5.2M

Oso Semiconductor has raised $5.2 million in seed funding. The round was led by Engine Ventures.
People

Battelle appoints Tim Ryan to board of directors

Battelle has elected Tim Ryan, Citi’s Head of Technology and Business Enablement, to its board of directors.
Around the web

OpenAI launches ChatGPT Gov for U.S. government agencies — CNBC

It’s called ChatGPT Gov and was built specifically for U.S. government use; writes Hayden Field. 
Around the web

DeepSeek’s popular AI app is explicitly sending US data to China — Wired

Users have already reported several examples of DeepSeek censoring content that is critical of China or its policies, writes Matt Burgess and Lily Hay Newman. 
Around the web

DeepSeek hit with large-scale cyberattack, says it’s limiting registrations — CNBC

DeepSeek on Monday said it would temporarily limit user registrations “due to large-scale malicious attacks” on its services; writes Hayden Field.